Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

Grunenthal

The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Grunenthal's 2013 immunology sales performance.

Graham Belgrave joins Cmed Clinical Sciences

Graham Belgrave joins Cmed Clinical Sciences He joins the UK-based firm from Grunenthal GmbH where he was senior vice president and global head of clinical development, science and operations.

Pharma deals in September 2015

Pharma deals in September 2015 It has received a positive EMA CHMP opinion and Grunenthal expects to launch Zalviso in the first half of 2016 and PDL expects to start to receive royalties thereafter. ... Specifically, PDL will receive 75% of the EU royalties under the Grunenthal

Grunenthal and AcelRx’s Zalviso approved in EU

Grunenthal and AcelRx’s Zalviso approved in EU delivery. AcelRx developed Zalviso and entered into a commercial collaboration with Grunenthal at the end of 2013. ... Grunenthal holds the rights for Zalviso in Europe and Australia while AcelRx retains all rights in North America.

Shire and Baxalta drugs among CHMP's latest recommendations

Shire and Baxalta drugs among CHMP's latest recommendations Grunenthal's Zalviso  (sufentanil) for the treatment of post-operative pain. A hybrid medicine, Zalviso's application relied in part on the results of studies carried out with a reference product

Pharma deals in June 2015

Pharma deals in June 2015 Collaboration, options to acquire and license. 105. Boston Children's Hospital/ Proteus/ Grünenthal.

[ Previous 5 results ] 1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Syneos Health™

Syneos Health™ is the only fully integrated biopharmaceutical solutions organization. Our company, including a Contract Research Organization (CRO) and Contract...

Latest intelligence

International Childhood Cancer Day 2019
The number of new cases per year is shocking but the journey and the outlooks have vastly improved. We've pulled together an infographic to show just what we mean with...
Immuno-oncology in 2019: the rapid evolution continues
Immunotherapy is pharma’s biggest growth driver – how will it develop in 2019?...
Mixing up Focus Groups
A nice spread of homogeneous participants in a focus groups are often a go to for reliable research outcomes but there's much to be said for mixing it up and...

Infographics